Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy
Facilitating Informed Decisions for Contralateral Prophylactic Mastectomy
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy
Facilitating Informed Decisions for Contralateral Prophylactic Mastectomy
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Click here to add this to my saved trials
Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Memorial Hospital
1289
mi
from
New York, NY
Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Memorial Hospital
1289
mi
from
New York, NY
Click here to add this to my saved trials
Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
Status: Enrolling
Updated:  12/31/1969
South Texas Accelerated Research Therapeutics
571
mi
from
San Antonio, TX
Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
Status: Enrolling
Updated: 12/31/1969
South Texas Accelerated Research Therapeutics
571
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
Status: Enrolling
Updated:  12/31/1969
Medical Oncology Clinic - Institut Jules Bordet
4720
mi
from
Brussels,
Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
Status: Enrolling
Updated: 12/31/1969
Medical Oncology Clinic - Institut Jules Bordet
4720
mi
from
Brussels,
Click here to add this to my saved trials
Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
Status: Enrolling
Updated:  12/31/1969
Stanford Cancer Center
1330
mi
from
Palo Alto, CA
Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
Status: Enrolling
Updated: 12/31/1969
Stanford Cancer Center
1330
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
Status: Enrolling
Updated:  12/31/1969
Roswell Park Cancer Institute
1057
mi
from
Buffalo, NY
Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression
Status: Enrolling
Updated: 12/31/1969
Roswell Park Cancer Institute
1057
mi
from
Buffalo, NY
Click here to add this to my saved trials
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer
A Phase 1b Study of PU-H71 With Nab-paclitaxel (Abraxane) in Patients With HER2-Negative Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer
A Phase 1b Study of PU-H71 With Nab-paclitaxel (Abraxane) in Patients With HER2-Negative Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Click here to add this to my saved trials
Long Term Use of SAVI SCOUT: Pilot Study
Evaluation of Longer Duration Use of the SAVI SCOUT Surgical Guidance System for Excision of Breast and Axillary Lesions in Neo-adjuvant Therapy Patients: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Envision Physician Scientific Research, Inc. formerly Sheridan Healthcare, Inc.
mi
from
Plantation, FL
Long Term Use of SAVI SCOUT: Pilot Study
Evaluation of Longer Duration Use of the SAVI SCOUT Surgical Guidance System for Excision of Breast and Axillary Lesions in Neo-adjuvant Therapy Patients: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Envision Physician Scientific Research, Inc. formerly Sheridan Healthcare, Inc.
mi
from
Plantation, FL
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Central Jersey Division
1264
mi
from
East Brunswick, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Central Jersey Division
1264
mi
from
East Brunswick, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Freehold Division
1269
mi
from
Freehold, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Freehold Division
1269
mi
from
Freehold, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
Hackensack Meridian Health System
1284
mi
from
Hackensack, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
Hackensack Meridian Health System
1284
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Hackettstown Division
1243
mi
from
Hackettstown, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Hackettstown Division
1243
mi
from
Hackettstown, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Howell Division
1274
mi
from
Howell, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Howell Division
1274
mi
from
Howell, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Little Silver Division
1283
mi
from
Little Silver, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Little Silver Division
1283
mi
from
Little Silver, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Marmora Division
1253
mi
from
Marmora, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Marmora Division
1253
mi
from
Marmora, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Mount Holly Division
1244
mi
from
Mount Holly, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Mount Holly Division
1244
mi
from
Mount Holly, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Pompton Plains Division
1271
mi
from
Pompton Plains, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Pompton Plains Division
1271
mi
from
Pompton Plains, NJ
Click here to add this to my saved trials
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated:  12/31/1969
RCCA - Sparta Division
1254
mi
from
Sparta, NJ
Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers
Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers
Status: Enrolling
Updated: 12/31/1969
RCCA - Sparta Division
1254
mi
from
Sparta, NJ
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Arizona Oncology Associates, PC - HOPE
832
mi
from
Tucson, AZ
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Arizona Oncology Associates, PC - HOPE
832
mi
from
Tucson, AZ
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Disney Family Cancer Center
1171
mi
from
Burbank, CA
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Disney Family Cancer Center
1171
mi
from
Burbank, CA
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Sharp Clinical Oncology
1140
mi
from
San Diego, CA
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Sharp Clinical Oncology
1140
mi
from
San Diego, CA
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Innovative Clinical Research Institute, LLC
1157
mi
from
Whittier, CA
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Innovative Clinical Research Institute, LLC
1157
mi
from
Whittier, CA
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Memorial UC Health
385
mi
from
Colorado Springs, CO
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Memorial UC Health
385
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Cancer Centers
417
mi
from
Lakewood, CO
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Cancer Centers
417
mi
from
Lakewood, CO
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists
1206
mi
from
Fort Myers, FL
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists
1206
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Research Institute
1302
mi
from
Plantation, FL
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Research Institute
1302
mi
from
Plantation, FL
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists - North (FCS North)
1116
mi
from
Saint Petersburg, FL
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists - North (FCS North)
1116
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
1112
mi
from
Tampa, FL
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
1112
mi
from
Tampa, FL
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Florida Cancer Specialists - East (FCS East)
1284
mi
from
West Palm Beach, FL
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Florida Cancer Specialists - East (FCS East)
1284
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Saint Alphonsus Regional Medical Center
1041
mi
from
Boise, ID
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Saint Alphonsus Regional Medical Center
1041
mi
from
Boise, ID
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Illinois Cancer Specialists
601
mi
from
Arlington Heights, IL
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Illinois Cancer Specialists
601
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Community Health Network
651
mi
from
Indianapolis, IN
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Community Health Network
651
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
University of Maryland Greenebaum Comprehensive Cancer Center
1148
mi
from
Baltimore, MD
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
University of Maryland Greenebaum Comprehensive Cancer Center
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Saint Luke's Cancer Institute
196
mi
from
Kansas City, MO
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Saint Luke's Cancer Institute
196
mi
from
Kansas City, MO
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Comprehensive Cancer Centers of Nevada
970
mi
from
Las Vegas, NV
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Comprehensive Cancer Centers of Nevada
970
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Levine Cancer Center
957
mi
from
Charlotte, NC
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Levine Cancer Center
957
mi
from
Charlotte, NC
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Forsyth Memorial Hospital, Novant Health Oncology Specialists
973
mi
from
Winston-Salem, NC
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Forsyth Memorial Hospital, Novant Health Oncology Specialists
973
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology PLLC
721
mi
from
Chattanooga, TN
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology PLLC
721
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Tennessee Oncology, PLLC
558
mi
from
Nashville, TN
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Tennessee Oncology, PLLC
558
mi
from
Nashville, TN
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology-Dallas Presbyterian Hospital
341
mi
from
Austin, TX
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology-Dallas Presbyterian Hospital
341
mi
from
Austin, TX
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology
511
mi
from
Austin, TX
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology
511
mi
from
Austin, TX
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology, P.A.
342
mi
from
Bedford, TX
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology, P.A.
342
mi
from
Bedford, TX
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology-Baylor Charles A. Sammons Cancer Center
347
mi
from
Dallas, TX
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology-Baylor Charles A. Sammons Cancer Center
347
mi
from
Dallas, TX
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - El Paso Cancer Treatment Center Grandview
641
mi
from
El Paso, TX
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - El Paso Cancer Treatment Center Grandview
641
mi
from
El Paso, TX
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
The Center for Cancer and Blood Disorders
348
mi
from
Fort Worth, TX
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
The Center for Cancer and Blood Disorders
348
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology-San Antonio Northeast
568
mi
from
San Antonio, TX
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology-San Antonio Northeast
568
mi
from
San Antonio, TX
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Tyler Hematology Oncology PA
401
mi
from
Tyler, TX
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Tyler Hematology Oncology PA
401
mi
from
Tyler, TX
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Texas Oncology
397
mi
from
Tyler, TX
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Texas Oncology
397
mi
from
Tyler, TX
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
University of Virginia
1049
mi
from
Charlottesville, VA
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
University of Virginia
1049
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Virginia Cancer Specialists, PC
1114
mi
from
Fairfax, VA
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)
Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Virginia Cancer Specialists, PC
1114
mi
from
Fairfax, VA
Click here to add this to my saved trials